US 12,479,870 B2
Base-modified cytidine nucleotides for leukemia therapy
Pedro Pinho, Huddinge (SE); Björn Klasson, Huddinge (SE); John Ohd, Huddinge (SE); and Mark Albertella, Huddinge (SE)
Assigned to MEDIVIR AB, Huddinge (SE)
Filed by MEDIVIR AB, Huddinge (SE)
Filed on May 21, 2024, as Appl. No. 18/670,555.
Application 18/670,555 is a continuation of application No. 17/254,099, abandoned, previously published as PCT/SE2019/050594, filed on Jun. 20, 2019.
Claims priority of provisional application 62/825,679, filed on Mar. 28, 2019.
Claims priority of application No. 1850765-7 (SE), filed on Jun. 21, 2018; and application No. 2019-090760 (JP), filed on May 13, 2019.
Prior Publication US 2024/0309031 A1, Sep. 19, 2024
Int. Cl. C07F 9/6558 (2006.01); A61P 35/02 (2006.01)
CPC C07F 9/65586 (2013.01) [A61P 35/02 (2018.01)] 17 Claims
 
1. A compound of the formula I

OG Complex Work Unit Chemistry
wherein X is a bond or —CH2-
or a pharmaceutically acceptable salt thereof.